8-A12B 1 d375989d8a12b.htm FORM 8-A12B Form 8-A12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-A

 

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 

UroGen Pharma Ltd.

(Exact name of registrant as specified in its charter)

 

 

 

State of Israel   Not Applicable
(State of incorporation or organization)   (I.R.S. Employer Identification No.)

 

9 Ha’Ta’asiya Street

Ra’anana 4365007

Israel

  Not Applicable
(Address of principal executive offices)   (Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

to be so registered

 

Name of each exchange on which

each class is to be registered

Ordinary Shares, par value NIS 0.01 per   The NASDAQ Stock Market LLC

 

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.  ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.  ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.  ☐

Securities Act registration statement or Regulation A offering statement file number to which this form relates:

333-217201 (if applicable)

Securities to be registered pursuant to Section 12(g) of the Act:

None

 

 

 


Item 1. Description of Registrant’s Securities to be Registered.

UroGen Pharma Ltd. (the “Registrant”) hereby incorporates by reference (a) the description of its Ordinary Shares, par value NIS 0.01 per share, to be registered hereunder under the heading “Description of Share Capital” and (b) the information set forth under the heading “Taxation” in the Registrant’s Registration Statement on Form F-1 (File No. 333-217201), initially filed with the Securities and Exchange Commission (the “Commission”) on April 7, 2017 (the “Registration Statement”), and any prospectus that constitutes part of the Registration Statement and that is subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which information shall be deemed to be incorporated herein by reference.

 

Item 2. Exhibits.

Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.


SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

    UroGen Pharma Ltd.
Date: May 1, 2017     By:  

/s/ Gary Titus

    Name:   Gary Titus
    Title:   Chief Financial Officer